Psychological Intervention
OtherThe intervention will include a psychological intervention with counseling sessions (online/video intervention) and telephone follow-up additionally to the care as usual.
NCT Number: NCT06017063
The aim is to improve patients' compliance to TTFields therapy by a psychological video intervention in a multi-center, randomized controlled trial.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Patients diagnosed with a glioblastoma and their family caregivers are mainly impaired by the poor prognosis and the high symptom burden. Caregivers report impaired health-related quality of life (HRQOL) and high distress. They even may experience significantly higher levels of anxiety and depression than patients themselves . Furthermore, Boele et al. showed that the overall survival in glioblastoma patients is associated with family caregivers' mastery.
In newly diagnosed glioblastoma, the EF-14 RCT demonstrated significantly prolonged survival in patients treated with TTFields compared to controls, with a median overall survival (OS) of 20.9 vs 16.0 months.
Several studies showed an important association of the daily compliance rate with OS and progression-free survival (PFS). Family caregivers' support might be associated to the patients' compliance and adequate support is required. However, so far rare supportive programs for patients and their caregivers have been established. It has been shown that delivery of supportive care via telehealth is feasible, however studies examining the effectiveness, adoption and maintenance of telehealth interventions in glioblastoma patients and family caregivers are still lacking. The aim is to improve patients' compliance to TTFields therapy by a psychological video intervention.
It is a multi-center, randomized controlled trial.
Main inclusion criteria are:
The experimental intervention is:
Delivery of supportive care via telehealth intervention (including a brief psychological intervention and information/educational support regarding the disease, therapy and self-help options) in family caregivers and patients
The intervention encompasses six interventions (video call) for patients and caregivers.
The six sessions will be conducted by the psychologists of the coordinating center to allow homogeneous and sound implementation of the BPI. All psychologists are certified psychooncologists.
The first part of the sessions is scheduled immediately after start of radiochemotherapy (+ 2 weeks) in order to guide patients and caregivers in this important phase after first diagnose.
The second part of the sessions is scheduled after completion of radiochemotherapy phase (+ 2 weeks) with focus in the adjuvant temozolomide therapy and TTFields therapy.
The control condition is: Standard of care with standard access to psychosocial support in certified Neuro-Oncological Centers
Primary Outcome:
Compliance to TTFields compared in intervention and control group
Secondary Outcomes:
Optional Outcomes:
On a voluntary basis the following biosamples will be acquired for assessment of stress level and immunogenic response
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The intervention will include a psychological intervention with counseling sessions (online/video intervention) and telephone follow-up additionally to the care as usual.
Time frame: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)
Compliance to TTFields compared in intervention and control group.Compliance will be measured by the duration of the TTFields application in each patient
Time frame: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)
Patient- and caregiver-reported acceptance of intervention as measured by number of patient and cargiver dyads who completed the 6th session of the psychooncological intervention
Time frame: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)
Adverse event of special interest: Skin irritation in patients under TTFields therapy
Time frame: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)
Caregiver emotional and physical well-being, patient emotional and physical well-being
Contact information is provided by the study sponsor or research team.
University Hospital Tuebingen
Other
Acronym: COCOON
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06464003
Behavior, Compliance, Patient
Helsinki, Finland
View Trial DetailsNCT05308914
Behavior, Cardiovascular Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT07066371
Anxiety, Anxiety Disorders
Bitlis, Turkey (Türkiye)
View Trial DetailsNCT04238949
Autoimmune Diseases, Behavior
Philadelphia, Pennsylvania, United States
View Trial Details